The Final Frontier
In this exclusive interview, Jim Mazzo talks about his new position on the Avellino Labs Board of Directors
Phoebe Harkin |
Let’s start with congratulations...
Thank you! All great things begin with one gamechanger – and, for gene therapy, I believe that is Avellino. We have fantastic technologies for the cornea, and we’re making steps in retina and glaucoma – but we’re not where we need to be just yet; that said, we’ve never had genetic testing in the eye before now, so I’m really happy to be part of the team bringing it to the market. The fact that much is still unknown about gene therapy excites me – and I know it excites our industry too. I’m honored to be able to work with Avellino.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.